ABSTRACT
Since 1995, the association between Anaplastic Large Cell Lymphoma (ALCL) and breast implant capsules has been of increasing concern. Up to 40 cases have been reported worldwide. The majority of cases favour an indolent course, similar to that of primary cutaneous ALCL, with a 10-year survival rate of greater than 90%. Many recommendations have been made for diagnosis, treatment and adjuvant therapy but the issue of reconstruction post capsulectomy and removal of implants has not yet been addressed. We present a case report and management option.
Subject(s)
Breast Implants/adverse effects , Breast Neoplasms/etiology , Breast Neoplasms/surgery , Lymphoma, Large-Cell, Anaplastic/etiology , Lymphoma, Large-Cell, Anaplastic/surgery , Seroma/pathology , Adult , Breast Implantation , Breast Neoplasms/pathology , Breast Neoplasms/radiotherapy , Device Removal , Dose Fractionation, Radiation , Female , Humans , Lymphoma, Large-Cell, Anaplastic/pathology , Lymphoma, Large-Cell, Anaplastic/radiotherapy , Recurrence , Reoperation , Seroma/etiology , Silicone GelsABSTRACT
A case of recurrent acute pancreatitis occurring in conjunction with intermittently used estrogen therapy over 7 years is presented. Estrogens have been associated with pancreatitis in the past, and a causal link involving elevated plasma triglyceride levels has usually been assumed. The current case is distinct in that the plasma lipids of this patient have always been normal, suggesting that a different mechanism must be responsible for the onset of pancreatitis.
